Article
Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
Pharmacogenetics and genomics - 1 Jan 2014
Dávila-Fajardo Cristina L, Márquez Ana, Pascual-Salcedo Dora, Moreno Ramos Manuel J, García-Portales Rosa, Magro César, Alegre-Sancho Juan J, Balsa Alejandro, Cabeza-Barrera José, Raya Enrique, Martín Javier
Abstract excerpt
BACKGROUND: The IL-6 -174G/C genetic variant has recently been associated with the clinical response to etanercept therapy in rheumatoid arthritis (RA) patients. Considering previous results, the aim of our study was to validate the role of this polymorphism as a predictor of the antitumor necrosis factor (anti-TNF) treatment outcome in RA. MATERIALS AND METHODS: Our study population was composed of 199 Spanish...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
